Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Piero Barbanti; Gabriella Egeo; Stefania Proietti; Florindo d’Onofrio; Cinzia Aurilia; Cinzia Finocchi; Laura Di Clemente; Maurizio Zucco; Alberto Doretti; Stefano Messina; Massimo Autunno; Angelo Ranieri; Antonio Carnevale; Bruno Colombo; Massimo Filippi; Miriam Tasillo; Steno Rinalduzzi; Pietro Querzani; Giuliano Sette; Lorenzo Forino; Francesco Zoroddu; Micaela Robotti; Alessandro Valenza; Cecilia Camarda; L. Borrello; Marco Aguggia; Giovanna Viticchi; Carlo Tomino; Giulia Fiorentini; Bianca Orlando; Stefano Bonassi; Paola Torelli

doi:10.1007/s40120-024-00648-z

Article2024

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, L. Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli

Article2021

Long-term (>48 weeks) safety and tolerability of erenumab in real-life

Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Sabina Cevoli, Roberta Messina, Antonio Salerno, Paola Torelli, Maria Albanese, Antonio Carnevale, Francesco Bono, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri, Bruno Colombo, Fabio Frediani, B. Mercuri, Florindo d’Onofrio, Licia Grazzi, Marco Aguggia, Valentina Favoni, Cinzia Finocchi, Paola Di Fiore, Carlemina Maria Costa,

Article2024

Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study

Massimo Filippi, Laura Zanandrea, Roberta Messina, Ilaria Cetta, Federica Genovese, Simone Guerrieri, Fabrizio Vernieri, Claudia Altamura, Sabina Cevoli, Valentina Favoni, Bruno Colombo

Corrigendum2022

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri

Corrigendum2022

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Discussion(0)

Related publications

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Long-term (>48 weeks) safety and tolerability of erenumab in real-life

Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Discussion(0)

Related publications

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Long-term (&gt;48 weeks) safety and tolerability of erenumab in real-life

Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Long-term (>48 weeks) safety and tolerability of erenumab in real-life